Lenalidomidă Labormed (Lenalidomide)

Lenalidomide exerts its antineoplastic activity by binding to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). The loss of these factors reduces malignant plasma‑cell proliferation, enhances immune‑mediated tumor cell killing, and inhibits angiogenesis, collectively slowing disease progression.

The dosage of Lenalidomidă Labormed is individualized and must be prescribed by a qualified healthcare professional. The prescriber determines the appropriate strength, schedule, and duration based on the specific indication, patient’s renal and hepatic function, and concomitant therapies. Patients should follow the exact dosing instructions provided on the prescription label and consult their oncologist for any adjustments.

Lenalidomidă Labormed is classified as pregnancy category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception during treatment and for a defined period after the last dose. The drug is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant. Discuss family planning with the treating physician.

To request Lenalidomidă Labormed, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials to verify eligibility. After verification, the sales team provides pricing, availability, shipping details—including any special handling—and assists with the necessary import documentation.

The primary alternative to lenalidomide in the same therapeutic class is thalidomide, another immunomodulatory agent. Compared with thalidomide, lenalidomide generally shows greater potency, a more favorable safety profile regarding peripheral neuropathy, and a reduced risk of severe constipation. However, both drugs share risks such as thrombosis and teratogenicity, and the choice between them depends on the specific disease, prior treatments, and patient tolerance.

Lenalidomidă Labormed should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in the original blister pack or container to protect them from moisture, light, and excessive heat. Do not store in the bathroom or near a kitchen stove. If the product appears discoloured or damaged, discard it according to local regulations and obtain a replacement.

Lenalidomidă Labormed is administered orally, typically as a whole tablet taken with water. The medication is usually taken on a scheduled cycle, such as daily for a set number of days followed by a rest period, but the exact regimen is defined by the prescribing oncologist. Patients should not crush, split, or chew the tablets unless specifically instructed, and should follow any dietary recommendations provided.

The most serious risks include thromboembolic events (deep‑vein thrombosis or pulmonary embolism), severe neutropenia that can lead to life‑threatening infections, hepatotoxicity with possible liver failure, and rare severe skin reactions such as Stevens‑Johnson syndrome. The drug is also teratogenic and can cause fetal harm. Patients should be monitored closely for clotting, infection, liver dysfunction, and skin changes, and report any concerning symptoms promptly.

Lenalidomidă Labormed is contraindicated in pregnant women and in individuals who are not using effective contraception during treatment and for the required post‑treatment period. Patients with uncontrolled active infections, severe hepatic impairment, or known hypersensitivity to lenalidomide or any excipients should also avoid the drug. Additionally, patients with a history of severe thromboembolic events should be evaluated carefully, and the medication may be withheld if the risk outweighs the benefit.